Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for KALA BIO, Inc. (KALA : NSDQ)

• Company Description    KALA BIO is a clinical-stage biopharmaceutical company. It focused on the research, development and commercialization of therapies for rare and severe diseases of the eye. The company' s lead product candidate consists KPI-012. KALA BIO, formerly known as Kala Pharmaceuticals Inc., is based in ARLINGTON, Mass. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $2.43 Daily Weekly Monthly 20 Day Moving Average: 87,785 shares Shares Outstanding: 18.59 (millions) Market Capitalization: $45.17 (millions) Beta: -2.23 52 Week High: $1,030.00 52 Week Low: $2.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -68.44% -69.98% 12 Week -87.21% -88.18% Year To Date -91.26% -91.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1167 MASSACHUSETTS AVENUE - ARLINGTON,MA 02476 USA ph: 781-996-5252 fax: 781-642-0399 taylor.steiner@precisionaq.com http://www.kalarx.com

• General Corporate Information    Officers Avi Minkowitz - Chief Executive Officer and Chief Financial Office Todd Bazemore - Chief Operating Officer and President Mary Reumuth - Chief Financial Officer Hillel Posen - Director Yonatan Colman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 483119301 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 18.59 Most Recent Split Date: 5.00 (0.02:1) Beta: -2.23 Market Capitalization: $45.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 99.80% vs. Previous Quarter: -100.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -1,336.10 12/31/25 - -12,971.16 09/30/25 - -2,323.94 ROA 03/31/26 - -94.85 12/31/25 - -90.83 09/30/25 - -86.99 Current Ratio 03/31/26 - 7.91 12/31/25 - 3.81 09/30/25 - 0.75 Quick Ratio 03/31/26 - - 12/31/25 - 3.81 09/30/25 - 0.75 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.58 12/31/25 - 12.56 09/30/25 - -61.71 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - - Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - -

Powered by Zacks Investment Research ©